The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
CorrectionsFull Access

Corrections

Published Online:

Correction

A problem in the Journal’s editorial offices caused an error of omission to occur in the reporting of competing interests for the February editorial “Defining the Boundaries of Childhood Bipolar Disorder” (Am J Psychiatry 2007; 164:185–188). The disclosure statement should have run as follows:

Dr. Martin reports no competing interests. Dr. Ghaemi currently receives research grants from GlaxoSmithKline and Pfizer; in the past year, he has been on the speakers’ bureaus of Abbott Laboratories, AstraZeneca, and GlaxoSmithKline; and in previous years has served on the advisory boards of Abbott Laboratories, GlaxoSmithKline, Janssen, and Pfizer. Neither he nor his family hold equity positions in pharmaceutical corporations. Dr. Freedman has reviewed this editorial and found no evidence of influence from these relationships.

Dr. Ghaemi had submitted his disclosure prior to publication, as required by Journal editorial policy.